loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Cipla Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Cipla Ltd. 13 May 2026 13:33 PM
Result PDF

Q4FY26 & FY26 Result Announced for Cipla Ltd.

Pharmaceuticals company Cipla announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Quarterly Revenue: Revenue from operations for Q4FY26 stood at Rs 6,541.20 crore, representing a decrease of 2.80% YoY compared to Rs 6,729.69 crore in Q4FY25. On a QoQ basis, revenue declined 7.54% from Rs 7,074.48 crore in Q3FY26.
  • Quarterly EBITDA: Consolidated EBITDA for Q4FY26 was Rs 997 crore, with an EBITDA margin of 15.2% of income from operations.
  • Quarterly Profit After Tax (PAT): PAT attributable to owners of the parent for Q4FY26 was Rs 554.64 crore, a decrease of 54.61% YoY from Rs 1,221.84 crore and a decline of 17.93% QoQ from Rs 675.80 crore.
  • Annual Revenue: For the full year FY26, consolidated revenue from operations reached Rs 28,162.59 crore, marking a growth of 2.23% YoY compared to Rs 27,547.62 crore in FY25.
  • Annual EBITDA: EBITDA for FY26 stood at Rs 5,925 crore, with a margin of 21.0%.
  • Annual Profit After Tax (PAT): Annual PAT attributable to owners for FY26 was Rs 3,879.23 crore, a decrease of 26.43% YoY compared to Rs 5,272.52 crore in FY25.
  • Cash Position: The company reported a strong net cash position of Rs 10,526 crore as of March 31, 2026.

Standalone Financial Highlights:

  • Quarterly Revenue: Standalone revenue from operations for Q4FY26 was Rs 4,209.98 crore, a decline of 12.25% YoY from Rs 4,797.89 crore and a decrease of 6.40% QoQ from Rs 4,498.08 crore.
  • Quarterly Profit After Tax (PAT): Standalone PAT for Q4FY26 was Rs 384.64 crore, down 74.11% YoY from Rs 1,485.40 crore and 37.65% QoQ from Rs 616.88 crore.
  • Annual Revenue: For the full year FY26, standalone revenue was Rs 18,979.95 crore, a marginal decrease of 0.34% YoY from Rs 19,044.85 crore in FY25.
  • Annual Profit After Tax (PAT): Standalone annual PAT stood at Rs 3,515.18 crore, a decline of 31.85% YoY from Rs 5,157.65 crore in FY25.
  • Dividend: The Board of Directors has recommended a final dividend of Rs 13 per equity share (face value of Rs 2 each) for the financial year ended March 31, 2026.

Business Highlights:

  • One India Business: This segment surpassed the Rs 12,500 crore annual revenue milestone in FY26. Quarterly sales for Q4FY26 grew by 15% YoY to Rs 3,007 crore.
    • Branded Prescription: Sustained growth in key chronic therapies (Respiratory, Urology, Anti-diabetes, and Cardiac). The chronic mix stood at 60.2%. The brand Foracort surpassed the Rs 1,000 crore threshold.
    • Trade Generics: Maintained strong double-digit growth supported by execution excellence and new introductions.
    • Consumer Health (CHL): Anchor brands like Nicotex, Omnigel, and Cipladine maintained leadership positions in their respective market segments.
  • North America: Delivered Q4FY26 revenue of USD 155 million and annual revenue of USD 780 million. The business secured regulatory approval for the first AB-rated gVentolin, the first commercial MDI product to be manufactured from the company's U.S. facility.
  • One Africa: Achieved robust quarterly growth of 21% YoY to Rs 1,236 crore. In South Africa specifically, quarterly revenue grew 33% YoY to Rs 984 crore.
  • Emerging Markets and Europe: The segment surpassed the USD 400 million annual revenue milestone. Q4FY26 sales stood at Rs 819 crore.
  • R&D Investments: For Q4FY26, R&D investment was Rs 509 crore, or 7.8% of sales, driven by product filings and development efforts.
  • Regulatory Update: USFDA completed inspections at manufacturing facilities in Bommasandra (Bengaluru), Sitec (Navi Mumbai), and Medispray (Goa), with all receiving 'VAI' or 'NAI' classifications.

Achin Gupta, MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In FY26, we recorded our highest-ever yearly revenue of Rs. 28,163 crore, reflecting the strength of our core businesses despite certain markets facing near-term challenges. Our One-India business surpassed the Rs. 12,500 crore annual revenue milestone. Key therapies in Branded Prescription business delivered robust double-digit growth, Trade Generics business sustained the strong growth momentum and anchor brands of Consumer Health Business maintained leadership position. The US business posted an annual revenue of USD 780 million supported by demand in our differentiated portfolio and a steady base business. In One Africa, we recorded a healthy annual growth of 7% YoY in USD terms, driven by firm performance across key markets. Emerging Markets and Europe crossed the USD 400 million annualised revenue threshold on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”.

Result PDF

Result PDF

Pharmaceuticals company Cipla announced Q3FY26 results

  • Revenue: Rs 7,074 crore against Rs 7,073 crore during Q3FY25, change 0%.
  • EBITDA: Rs 1,255 crore against Rs 1,989 crore during Q3FY25, change -37%.
  • EBITDA Margin: 17.7% for Q3FY26.
  • PAT: Rs 676 crore against Rs 1571 crore during Q3FY25, change -57%.

Umang Vohra, MD & Global CEO, Cipla & Achin Gupta, MD & Global CEO (Designate), Cipla, said: “We are pleased to share that we continue to make considerable progress across our focused markets. In Q3FY26, we delivered global revenues of Rs 7,074 crore, despite the known drop in gRevlimid sales. Our OneIndia business grew at solid 10% YoY. Branded Prescription business delivered a double-digit growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of Consumer Health Business maintained leadership position. The US business posted a revenue of USD 167 million during the quarter. Our upcoming launches are expected to cushion gRevlimid revenue decline and provide long-term growth. Our South Africa private business continued to grow faster than the market. Emerging Markets and Europe continued its growth trajectory with revenue growth of 7% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.”

Result PDF

Pharmaceuticals company Cipla announced Q2FY26 results

  • Income from Operations: Rs 7,589 crore compared to Rs 7,051 crore during Q2FY25, change 7.6%.
  • EBITDA: Rs 1,895 crore compared to Rs 1,886 crore during Q2FY25, change 0.5%.
  • EBITDA Margin: 25.0% for Q2FY26.
  • PAT: Rs 1,351 crore compared to Rs 1,303 crore during Q2FY25, change 3.7%.

Umang Vohra MD & Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q2FY26, we delivered our highest-ever quarterly revenue of Rs 7,589 crore, with a robust EBITDA margin of 25%. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets. Our One-India business grew at 7% YoY. Key therapies in Branded Prescription business continued to deliver strong market growth and with the launch of Yurpeak® (Tirzepatide), we mark a pivotal step into obesity care through our strategic partnership with Eli Lilly. Trade Generics recorded a double-digit growth and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of USD 233 million during the quarter. In Q3FY26, gRevlimid is expected to have a small contribution to the US revenue, with the base business expected to continue growing. Upcoming launches, subject to USFDA approvals, are expected to alleviate gRevlimid revenue decline over the next four quarters, though there may be a timing gap before the full benefit is realized. In One Africa, we achieved a healthy growth of 5% YoY in USD terms. Emerging Markets and Europe delivered a solid revenue growth of 15% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front. “

Result PDF

Pharmaceuticals company Cipla announced Q1FY26 results

  • Income from Operations: Rs 6,957 crore compared to Rs 6,694 crore during Q1FY25, change 3.9%.
  • EBITDA: Rs 1,778 crore compared to Rs 1,716 crore during Q1FY25, change 3.6%.
  • EBITDA Margin: 25.6% for Q1FY26.
  • PAT: Rs 1,298 crore compared to Rs 1,178 crore during Q1FY25, change 10.2%.

Umang Vohra MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of $ 226 Mn. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging Markets and Europe delivered a substantial revenue growth of 20% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front."

Result PDF

Pharmaceuticals company Cipla announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Income from Operations: Rs 6,730 crore compared to Rs 6,163 crore during Q4FY24, change 9.2%.
  • EBITDA: Rs 1,538 crore compared to Rs 1,316 crore during Q4FY24, change 16.8%.
  • EBITDA margin: 22.8% for Q4FY25.
  • PAT: Rs 1,222 crore compared to Rs 939 crore during Q4FY24, change 30.1%.

FY25 Financial Highlights:

  • Income from Operations: Rs 27,548 crore compared to Rs 25,455 crore during FY24, change 8.2%.
  • EBITDA: Rs 7,128 crore compared to Rs 6,233 crore during FY24, change 14.4%.
  • EBITDA margin: 25.9% for FY25.
  • PAT: Rs 5,273 crore compared to Rs 4,106 crore during FY24, change 28.4%.

Umang Vohra MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of USD 934 million. In One Africa, we recorded a solid growth of 12% YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”.

Result PDF

Pharmaceuticals company Cipla announced Q3FY25 results

  • Income from Operations: Rs 7,073 crore, change 8% YoY.
  • EBITDA: Rs 1,989 crore, change 16% YoY.
  • EBITDA margin: 28.1% for Q3FY25.
  • PAT: Rs 1,571 crore, change 50% YoY.
  • PAT margin: 22.2% for Q3FY25.

Umang Vohra MD & Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of USD 226 million. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging Markets and Europe delivered a substantial revenue growth of 20% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”.

Result PDF

Pharmaceuticals company Cipla  announced Q2FY25 results

Financial Highlights:

  • Highest-ever quarterly Revenue and EBITDA margin at 26.7%.
  • Income from Operations: Rs 7,051 crore, change 9% YoY.
  • EBITDA: Rs 1,886 crore, change 12% YoY.
  • EBITDA margin: 26.7%.
  • PAT: Rs 1,303 crore, change 17% YoY.
  • PAT Margin: 18.5%.

Business Highlights:

  • One India Business grew at 5% YoY. Branded Prescription business continued to outpace the market in key Chronic therapies. CHL delivered strong growth at 21% YoY. The business however, witnessed a historically slow seasonal growth in Acute category impacting both Branded Prescription and Trade Generics business.
  • Delivered quarterly revenue of USD 237 million up by 4% YoY supported by traction in differentiated portfolio.
  • Progressing on the journey of strengthening the Africa story, the North Africa business which was a part of Emerging markets and Europe is now merged with SAGA region which is renamed as One Africa. Momentum continues with overall revenue growth at 22%.
  • Emerging Markets and Europe: Posted a robust revenue growth of 18% in USD terms.
  • R&D investments: stand at INR 385 crore or 5.5% of sales, higher by 2% YoY driven by product filings and developmental efforts.
  • Net cash position of Rs 7,950 crore; Debt primarily includes lease liabilities and working capital requirements.

Umang Vohra MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q2FY25, we recorded a revenue growth of 9% over last year with a highest-ever EBITDA margin of 26.7%, driven by mix and other operational efficiencies. Our One-India business was impacted during the quarter due to changed seasonal pattern, however key chronic therapies in Branded Prescription business continued to grow faster than the market. Consumer health business grew at a strong 21% YoY. With our concentrated focus in differentiated portfolio, the US business posted a revenue of USD 237 million. In South Africa, we recorded a solid growth of 22% YoY in local currency terms, led by Private Market. Emerging Markets and Europe delivered a robust revenue growth of 18% YoY on the back of deep market focus strategy. Going ahead, focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”.

Result PDF

Pharmaceuticals company Cipla announced Q1FY25 results:

Financial Highlights:

  • Income from Operations: Rs 6,694 crore, up by 7% YoY
  • EBITDA: Rs 1,716 crore, up by 14% YoY
  • PAT: Rs 1,178 crore, up by 17% YoY

Business Highlights:

  • One-India: India Branded Prescription Business grew at a healthy rate of 10% YoY. Overall One India growth was offset by softness in Trade Generics Business owing to distribution model change.
  • North America: All-time high revenue at USD 250 million up by 13% YoY supported by traction in differentiated portfolio.
  • South Africa: Momentum continues with revenue growth at 19% in local currency terms. Prescription business ranked #1 in the market
  • R&D investments: stand at Rs 353 crore or 5.3 % of sales, higher by 1% YoY driven by product filings and developmental efforts.
  • Strong net cash: Net cash position of Rs 8,449 crore; Debt primarily includes lease liabilities and working capital requirements.
  • Compliance update: Patalganga and Kurkumbh facilities were classified as ‘VAI’ by USFDA.

Umang Vohra MD and Global CEO, Cipla said: I am pleased to share that we continue to make considerable progress across our focused markets. In Q1FY25, we recorded revenue growth of 7% over last year with EBITDA margin of 25.6% driven by mix and other operational efficiencies. Our One-India business continued on its growth trajectory during the quarter, led by Branded Prescription which grew at 10%. Our concentrated focus and execution in differentiated portfolio have further strengthened the US business which yet again posted all-time high quarterly revenue at USD 250 million. In South Africa, we recorded a solid growth of 19% YoY in local currency terms, led by Private Market. Going ahead, focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”.

Result PDF

Pharmaceuticals company Cipla announced Q4FY24 & FY24 results:

FY24 Financial Highlights:
For the fiscal year 2024, Cipla's annual revenue surpassed Rs 25,000 crore with a growth of 14% YoY, while the Profit After Tax (PAT) soared by an impressive 47% YoY to Rs 4,106 crore.

Q4FY24 Financial Highlights:

For Q4FY24, Cipla's revenue was Rs 6,163 crore with a growth of 10% YoY, while the Profit After Tax (PAT) soared by an impressive 79% YoY to Rs 939 crore.

Umang Vohra MD and Global CEO, Cipla, said “I am pleased to share our performance for the year where we made substantial progress across our focused markets. In FY24, our revenues crossed the threshold of Rs 25,000 crore whereas operating margins significantly improved to cross Rs 6,000 crore for very first time, growing at healthy 14% on topline and 26% on profitability YoY. This was backed by One-India revenue breaching Rs 10,000 crore, North America revenue surpassing USD 900 million and South Africa reaching top spot in prescription market, with all three businesses growing in double digits over last year with improved profitability. As we enter into FY25, our focus will be on our priorities of market leading growth in our key markets, growing big brands bigger, investing in future pipeline as well as focusing on resolutions on regulatory front”.

Result PDF

Pharmaceuticals firm Cipla announced Q3FY24 result:

Financial Highlights:

  • Income from Operations: Rs 6,544 crore, representing a 14.2% YoY increase.

  • EBITDA: Rs 1,720 crore, translating to 26.3% of Income from Operations, reflecting a 24.9% YoY growth.

  • Profit After Tax (PAT): Rs 1,049 crore, marking a substantial increase of 32.7% YoY.

Business Performance by Region:

  • One-India: Revenue growth stood at 12% YoY, bolstered by Branded Prescription, Trade Generics, and Consumer Health verticals. The market share for chronic therapy increased by 115 bps YoY to 60.3%.
  • North America: Recorded highest ever quarterly revenue at $230 Mn, an 18% YoY growth, driven by volume traction in key assets such as Lanreotide and Albuterol, along with strong base business demand.
  • South Africa: Demonstrated a 15% growth in local currency terms YoY, fueled by strong performance across prescription, OTC, and tender segments.

Research and Development (R&D):

  • Investment: R&D investments were reported at Rs 400 crore or 6.1% of sales, showcasing an increase of 10% YoY.

Balance Sheet Health:

  • Robust Net Cash Position: Rs 7,143 crore post the repayment of ZAR 720 Mn term loan in South Africa.

Umang Vohra, MD and Global CEO of Cipla Ltd, stated: "I am happy to announce results for yet another quarter which further established our strengths of our core business in India, North America, and South Africa. Our topline growth for the quarter was at an impressive 14% YoY with strong EBITDA margins at 26.3%. One India business grew at a healthy 12% YoY backed by strong performance across Branded Prescroreiption, Trade Generics and Consumer Health. In North America, we continue to scale newer peaks by posting the highest ever quarterly revenue yet again at $ 230 Mn, supported by positive traction in key assets and base business. Our South Africa business further extended its momentum from last quarter by growing at 15% in local currency terms driven by strong execution across prescription, OTC, and tender. Our focus continues on expansion in chronic therapies, growing big brands, global wellness as well as developing our R&D pipeline in respiratory and peptides. We will continue to focus on driving profitable growth across businesses".

 

 

Result PDF

Trending News

L&T partners with Exail to offer advanced drone mine-sweeping tech for 12 Indian Navy vessels

Larsen & Toubro has entered into a strategic partnership with Exail to jointly offer an advanced Unmanned Mine Counter-Measure (MCM) Suite for the Indian Navy’s proposed programme of 12 Mine Counter Measure Vessels (MCMVs). 

Published on 15-May-2026 09:59

JSW Steel Q4 PAT hits ₹3,475cr; board approves ₹14,000cr fundraising and BMM Ispat merger

JSW Steel reported a healthy performance in Q4FY26. Consolidated topline stood ₹51,180 crore (up 14% YoY and 11% QoQ) with steel sales volume of 8 MT (up 6% YoY and 4% QoQ). 

Published on 15-May-2026 09:19

HCLTech to lead $300M round in AI startup Sarvam AI at $1.5B valuation

As per media reports, HCLTech is reportedly set to lead a $300 million funding round in Indian foundational AI startup Sarvam AI with an investment of around $150 million. 

Published on 15-May-2026 09:17

Chalet Hotels Q4 PAT jumps 32% to ₹163cr; annuity business revenue surges 37

Chalet hotels ltd. reported high single digit growth in consolidated revenues driven largely by double digit revenue growth in the annuity business. 

Published on 15-May-2026 09:16

Pearl Global Q4 PAT beats estimates, jumps 30% to ₹81.4cr; 20% dividend payout policy set

Pearl Global Industries (PGIL) reported in-line revenue growth and beat on EBITDA and PAT estimates. 

Published on 15-May-2026 09:15

HAL Q4 PAT rises 5.5% to ₹4,196cr; full-year FY26 net profit hits ₹9,116cr

HAL reported Q4FY26 revenue of ₹13,942 crore (+1.8% YoY and +81.1% QoQ), led by healthy execution across key aerospace and defence programmes during the quarter. 

Published on 15-May-2026 09:14

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app